🧵 “ANCA Vasculitis: 10 Updated Guideline Pearls (ACR 2021–2022)”...

Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) require urgent, precise treatment.
Here are the latest evidence-based recommendations 👇
#Rheumatology #MedTwitter #ClinicalPearls #Vasculitis @IhabFathiSulima @DrAkhilX @JasmineNephro
✅ Suspect in patients with:
•Rapidly progressive glomerulonephritis
•Pulmonary hemorrhage
•Chronic sinusitis refractory to treatment
•Mononeuritis multiplex
✅ PR3-ANCA (c-ANCA): More common in GPA
✅ MPO-ANCA (p-ANCA): More common in MPA
✅ ~10% are ANCA-negative—biopsy remains gold standard.
✅ Rituximab preferred for most patients (RAVE trial).
✅ Cyclophosphamide still recommended for:
•Severe renal dysfunction
•Severe alveolar hemorrhage
✅ No longer routine after PEXIVAS trial.
✅ Consider only if:
•Severe alveolar hemorrhage
•Rapid progression to dialysis
✅ ACR 2021: Reduce prednisone to ≤7.5 mg/day by 6 months.
✅ Faster taper reduces infections and side effects.
✅ Rituximab shown superior in sustaining remission (MAINRITSAN trial).
✅ Re-dosing every 6 months or tailored based on B-cell repopulation.
✅ Prevents Pneumocystis jirovecii pneumonia and reduces GPA relapse risk.
✅ Especially after repeated rituximab.
✅ Consider IVIG replacement if severe infections occur.
✅ ~50% risk within 5 years.
✅ Monitor renal function, symptoms, and ANCA titers (helpful but not definitive).
✅ Early collaboration with nephrology, pulmonology, ENT improves outcomes.
✅ Vaccination and infection prevention are critical.
ANCA vasculitis management is evolving—faster tapers, less plasma exchange, rituximab preferred for maintenance.
✅ Master these updates—timely treatment preserves life and organ function.
🩺 Follow @Rheumat_Aravind for clear, practical autoimmune insights.
#Vasculitis #Rheumatology #Autoimmune #MedEd #ClinicalPearls #MedTwitter